The Divisions of Hematology and Oncology have a long history of providing compassionate, personal service to those suffering from cancer and blood disorders. The Divisions are leaders in early drug development, human cancer genetics, and biological response modifiers in the treatment of cancer and its complications. Molecular biology, pharmacology, biochemistry and basic immunology are integral parts of the Division's developmental therapeutics and cancer immunology programs. The Divisions of Hematology and Oncology have 50 faculty who see over 1,500 outpatients/month at clinic facilities within the James Cancer Center, Kenny Road, and Stoneridge. In addition, the faculty care for over 2,560 inpatients at The Arthur G. James Cancer Hospital and Richard J. Solve Research Institute (The James), an NCCN designated free standing comprehensive cancer center, where patients with the primary diagnosis of cancer are seen and treated. The James houses 180 inpatient beds and services 40 cancer specific clinics and is continuing to expand to accommodate additional faculty, patients, and research missions.
Trainees will qualify for examination by the American Board of Internal Medicine in medical oncology or hematology/oncology after successful completion of the two or three-year program, respectively. The program’s primary objective is to train clinically competent, compassionate, board eligible physicians with a broad knowledge of medical oncology and hematology through a combination of intensive inpatient service exposure on Oncology, Hematology, Leukemia, Stem cell transplant, and Consult service; rotations including Gynecology/Oncology, Radiation Oncology, Neuro-Oncology, Hematopathology, Blood banking, and Hospice and Palliative Care, and broad outpatient exposure through continuity, ambulatory, and elective clinic blocks. In addition, fellows are required to dedicate a portion of their fellowship to either laboratory-based research or clinical research which provides training in laboratory assays in cancer medicine, conducting and reporting clinical trials, and communication with other physician scientists. Finally, the program offers a wealth of didactic and patient-oriented educational experiences through weekly formal case review conferences, journal club, tumor boards, board review, basic lecture series, and teaching attending rounds.
The strengths of our program include rigorous clinical training, with exposure to a diverse patient population, a wealth of educational opportunities, experienced mentors, and committed time to pursue either laboratory and patient-oriented/translational research. Many of our faculty are world-recognized experts in the fields of hematology and oncology and are committed to clinical and laboratory-based research.
We hope you find our web site useful and we appreciate your interest in our program. For additional information on the James please click here cancer.osu.edu.